Fluticasone propionate/formoterol fumarate combination therapy is more effective than fluticasone propionate alone in the treatment of asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma Source: Annual Congress 2011 - Treating childhood asthma Year: 2011
Fluticasone propionate/formoterol fumarate combination therapy has superior efficacy to both fluticasone and formoterol alone Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD Source: Eur Respir J 2014; 43: 763-772 Year: 2014
Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids Source: Eur Respir J 2002; 19: 182-191 Year: 2002
Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Asthma exacerbation with fluticasone propionate/formoterol fumarate combination therapy versus its individual components Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Comparison of inhaled ciclesonide, fluticasone propinate and fluticasone propionate + salmeterol in maintaining asthma control Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Response to therapy with fluticasone propionate/salmeterol 250/50 or ipratropium/albuterol in population subgroups of patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005
Efficacy and safety of the new beclomethasone dipropionate/formoterol combination vs. fluticasone propionate/salmeterol pMDIs in moderate to severe persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma Source: Eur Respir J 2007; 29: 682-689 Year: 2007
Low-dose fluticasone is superior to montelukast in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 262s Year: 2001
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma Source: Eur Respir J 2014; 43: 773-782 Year: 2014
Cost-effectiveness of budesonide and formoterol in a single inhaler compared to fluticasone in the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001
Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004